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Introduction
Adipocytes are a key component of adipose tissue that play a sig-
nificant role in maintaining energy homeostasis, and this role is 
not limited to simple, direct regulation of glucose and lipid lev-
els. Recent studies suggest that adipose tissue serves as a crucial 
integrator of glucose homeostasis through endocrine function 
of adipocytes. Several mechanisms have been identified that are 
related to cross-talk between the adipose tissue, skeletal muscle, 
liver, pancreas, brain, and immune system. These mechanisms 
involve both increased free fatty acid release and altered secre-
tion of numerous proteins from adipose tissue. Secreted proteins 
such as leptin, adiponectin, resistin, tumor necrosis factor-α and 
other cytokines, omentin, and visfatin coordinate the metabol-
ic activities of various organs and affect several metabolic and 
regulatory pathways [1, 2]. In many metabolic disorders, the 
function of adipose tissue is disturbed, and the role of adipo-
cytes changes significantly; this is not limited to obesity or type 
2 diabetes. Furthermore, the targeting of adipose physiology is 
a promising approach for the treatment of these conditions [3, 4].
Differentiation of preadipocytes to adipocytes (adipogene-
sis) is regulated by a set of transcription factors responsible for 
the expression of key proteins that induce mature adipocyte 
formation [5]. These proteins include peroxisome prolifera-
tor-activated receptor γ (PPARγ), CCAAT/enhancer-binding 
protein (C/EBP) family members, and sterol regulatory element 
binding protein 1c (SREBP-1c). These factors can modulate the 
expression of downstream target genes involved in lipogenesis 
and lipolysis, such as acetyl-CoA carboxylase (ACC) or fatty 
acid synthase (FAS) [6, 7]. The changes characteristic of adi-
pocyte maturation included also insulin receptor (INS-R), glu-
cose transporter type 1, 3 and 4 (GLUT 1, 3, 4) and glucokinase 
(GCK) regulated glucose transport and metabolism [8].
A current pharmacological approach to treat insulin resist-
ance and type 2 diabetes is the use of thiazolidinediones (TZDs), 
which are agonists of PPARγ and promote the differentiation of 
preadipocytes into adipocytes, while the sulfonylureas stimu-
late insulin secretion by blocking ATP-dependent potassium 
channels of pancreatic β-cells and induce the differentiation of 
human preadipocytes [9, 10, 11]. 
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Abstract
Recent research on the action of vanadium compounds shows its important effect on adipo-
genesis processes and adipocyte function. On the basis of previous screening tests in cellular 
models, the novel vanadium complex (N′-[(E)-(5-bromo-2-oxophenyl)methylidene]-4-methox-
ybenzohydrazide)oxido(1,10-phenanthroline)vanadium(IV) was selected for this study. This 
complex exhibits potent inhibition of tyrosine phosphatases, and differences in the degree of 
inhibition were observed particularly for phosphatases. A significant increase in intracellu-
lar lipid accumulation and proliferative effect on 3T3-L1 preadipocytes confirmed the ability 
of this complex to enhance adipogenesis. The insulinomimetic activity of the tested complex 
was also demonstrated in fully differentiated 3T3-L1 adipocytes, in which glucose utilization 
was potentiated. The obtained results support the hypothesis that vanadium complexes show 
promising possibilities for use as new therapeutic strategies for the treatment of type 2 diabetes.
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The compounds that modulate the functions of adipocytes 
and adipose tissue also include vanadium inorganic salts and 
vanadium complexes, whose insulinomimetic effects have 
been demonstrated on isolated adipocytes in the 1980s [12]. 
The mechanisms of metabolism-modifying action of vanadi-
um compounds, including the pronounced antidiabetic effects, 
are largely associated with the ability of vanadium to inhibit 
tyrosine phosphatases. The results of previous studies indicate 
the importance of inhibiting this class of phosphatases in the 
cellular physiology of adipocytes, which suggest the potential 
significance of vanadium in the modulation of these processes. 
Several protein-tyrosine phosphatases have been identified in 
major insulin-sensitive tissues and also in adipose tissue. These 
include transmembrane phosphatases such as leukocyte com-
mon antigen-related phosphatase (LAR) and CD45 and non-
transmembrane phosphatases such as PTP1B, PTP1C, SHP1, 
SHP2, and PTPRQ. These phosphatases are known as impor-
tant factors that modulate insulin-related signal transduction 
and increase insulin sensitivity, glucose uptake, and resistance 
to obesity [13, 14, 15]. A small number of studies on the effect 
of vanadium compounds on adipocytes have been carried out; 
thus, the mechanisms by which vanadium targets preadipocytes 
and adipocytes are not fully elucidated.
3T3-L1 preadipocytes are the widely used cell model in re-
search on adipocyte biology and the pharmacological action of 
compounds with potential applications in pharmacotherapy. 
3T3-L1 cells are suitable models for assessing preadipocyte dif-
ferentiation and for studying lipid and glucose metabolism [16]; 
furthermore, several studies on the effect of vanadium com-
pounds on this cell model have been conducted. Bis(allixinato)
oxovanadium(IV) stimulates the translocation of GLUT4 to the 
plasma membrane in 3T3-L1 adipocytes following the activation 
of tyrosine phosphorylation of the insulin receptor beta-subunit 
(IR) and insulin receptor substrate (IRS) as well as Akt kinase 
[17]. Similar targets were identified for bis(alpha-furancarboxy-
lato)oxovanadium(IV) (BFOV)-enhanced expression of IRS-1 
and GLUT4 mRNA, which can explain the improvement of dexa-
methasone-induced insulin resistance in 3T3-L1 adipocytes [18]. 
Bis(acetylacetonato)-oxovanadium(IV) (VO(acac), bis(maltola-
to)-oxovanadium(IV) (BMOV), and sodium metavanadate 
(NaVO3) attenuated lipolysis, and both Akt and ERK pathways 
were activated by these compounds; however, only Akt activation 
contributes to the antilipolytic effect of the vanadium compounds, 
without the involvement of ERK activation [19]. Other factors are 
also affected by vanadium. Vanadyl sulfate (VOSO4) increased 
adiponectin cell content and release from 3T3-L1 adipocytes 
through a PKB-dependent transduction pathway [20].
Most studies on the effect of vanadium compound on 3T3-L1 
cell model have focused on the effects of vanadium on matured, 
fully differentiated adipocytes; however, recent research in the 
adipogenic action of vanadium compounds, show limited but 
important influence on this process. 
Three novel synthesized binary vanadium (V)-Schiff base 
complexes induce differentiation of 3T3-L1 preadipocytes into 
mature adipocytes, and this effect is comparable to the differen-
tiation effect induced by insulin; further, in combination with in-
sulin, vanadium showed potential synergistic interactions. Differ-
entiated mature adipocytes showed strong increase in GLUT4 as 
compared to undifferentiated pre-adipocytes; this indicates a pos-
sible mechanism for the observed effects [21]. Interestingly, vana-
dium(IV)-chlorodipicolinate (VOdipic-Cl) showed the opposite 
effect on adipogenesis in 3T3-L1 preadipocytes and inhibited 
preadipocyte differentiation and adipogenesis by activating the 
LKB1/AMPK-dependent signaling pathway [22]. These findings 
indicate the potential use of vanadium complexes as promising 
agents in the treatment of metabolic diseases such as obesity or 
diabetes type 2, where inhibition or activation of adipogenesis is 
an important pathogenetic and therapeutic mechanism. 
In the present study, a new vanadium complex N’-[(E)-(5-
bromo-2-oxophenyl)methylidene]-4-methoxybenzohydrazide)
oxido(1,10-phenanthroline)vanadium(IV) (complex (1)) was 
selected on the basis of results of screening tests in three cell-
based models [23]. 
The aim of this study was assessment of this vanadium com-
plex on adipogenesis and differentiation of 3T3-L1 cells.
Methods
Inhibition of human PTP1B, SHP1, SHP2 and LAR 
phosphatases
Test and reference compounds were dissolved in dimethyl sul-
foxide (DMSO) at a concentration of 10 mM and further diluted 
in phosphate buffered saline (PBS). The final concentrations 
of compounds were 10 µM (0.1% DMSO) and 1 µM (0.01% 
DMSO). All reactions were carried out at room temperature in 
black 384-well plates (Perkin Elmer). To the solution of the test 
compounds an equal volume of a test solution of phosphatase 
(50 ng/mL PTP1B, 400 ng/mL SHP1, 50 ng/mL SHP2, and 5 ng/
mL LAR) in a reaction buffer: 25 mM of 3-(N-morpholino) pro-
panesulfonic acid (MOPS), 50 mM NaCl, 1 mM dithiothreitol 
(DTT), and 0.05% Tween-20, pH 7.0. After 10 minutes, a solu-
tion of phosphate 6,8-difluoro-4-methylumbelliferyl phosphate 
(DiFMUP) was added until its final concentration was 0.1 mM. 
After 20 minutes of incubation at room temperature, the fluo-
rescence intensity (355 nm excitation and 560 nm emission) was 
measured on a multifunction plate reader (POLARstar Ome-
ga, BMG Labtech, Germany) [24, 25]. Assays were conduct in 
triplicates. The results were normalized to the untreated control 
(phosphatase with solvent only), wherein the intensity of fluo-
rescence was taken as 100%.
Cell models
3T3-L1 cell line (ATCC CL-173) derived from fibroblasts of 
mouse embryo tissue was cultured according to a standard pro-
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tocol in DMEM medium supplemented with 10% bovine calf 
serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin at 
37°C in 5% CO2.
For differentiation experiments, the cells were seeded in 96-
well poly-D-lysine-coated plates and cultured to reach conflu-
ency. The medium was then (differentiation day 0) switched to 
differentiation medium I (DMEM, 10% fetal bovine serum, 25 
nM 3-isobutyl-1-methylxanthine (IBMX), 500 µM dexameth-
asone, and 670 nM insulin). After 48 hours of incubation (dif-
ferentiation day 2), the medium was changed to differentiation 
medium II (DMEM, 10% fetal bovine serum, and 670 nM insu-
lin), and tested reference compounds and vanadium complexes 
were added. After 24 hours of incubation (differentiation day 
3), cell number, intracellular lipid accumulation, and glucose 
concentration were determined. To assess the influence of va-
nadium complexes on the later phase of differentiation process, 
3T3-L1 cells were treated as above but without the addition of 
tested compounds, and differentiation medium II was replaced 
with DMEM with 10% fetal bovine serum. In this medium, the 
cells were maintained until the seventh day of differentiation, 
and then tested reference compounds and vanadium complexes 
were added for 24 hours, and cell number, intracellular lipid ac-
cumulation, and glucose concentration were determined (differ-
entiation day 8). Incubation of cells with vanadium complexes 
was performed in triplicates, and each compound was tested in 
two to three independent experiments [26, 27]. Lipid accumu-
lation, glucose utilization and cell number were determined in 
each well.
Lipid accumulation 
After incubation with tested compounds 3T3-L1 cells were 
washed with PBS with calcium and magnesium and 5 µl Adi-
poRed reagent (Lonza) in 200 µl PBS was added and incubated 
for 10 minutes in 22°C. Fluorescence signal proportional to li-
pids content in cells was measured at excitation in 530 nm and 
emission in 550 nm using multimodal microplate reader PO-
LARStar Omega (BMG Labtech). The results were normalized 
to the untreated control (cells with solvent only), wherein the 
intensity of fluorescence was taken as 100%.
Glucose utilisation
After incubation, supernatants from 3T3-L1 cells were collected 
and glucose concentration was determined based on enzymatic 
reaction with glucose oxidase. End product of the reaction was 
determined fluorometrically using Amplex Red Glucose/Glu-
cose Oxidase Kit (Invitrogen) according to manufacturer proto-
col. 10 µl supernatant diluted in 50 mM PBS pH 7.4 and 10 µl re-
agents contained 4 U/ml glucose oxidase, 0.4 U/ml horseradish 
peroxidase and 200 µM 10-acetyl-3,7-dihydroxyphenoxazine in 
50 mM PBS pH 7.4 was added to 384-well black microplate and 
incubated for 30 minutes at 37°C. All assays were conducted 
in triplicates. Fluorescence signal was measured at excitation in 
530 nm and emission in 580 nm using multimodal microplate 
reader POLARStar Omega (BMG Labtech) and glucose con-
centration in samples was calculated in MARS Data Analysis 
Software based on glucose standards. Glucose utilisation was 
Experiment 
day
Treatment of the cells
in early phase of differentiation
Experiment day
Treatment of the cells
in late phase of differentiation
0
IBMX + dexamethasone + insulin  
in DMEM + FBS
0
IBMX + dexamethasone + insulin  
in DMEM + FBS
2
Tested and control compounds 50 µM + 
insulin in DMEM  
+ FBS 2 - 7 DMEM + FBS alone 
3 Experiment readout and assays
7 - 7
Tested and control compounds 50 µM in 
DMEM + FBS
8 - 8 Experiment readout and assays
Untreated control Medium (DMEM + FBS) + vehicle
Differentiated control Inductors of differentiation (IBMX + DEX + INS) in medium
Negative control Isoproterenol 50 µM (as lipolytic agent) added at the same time as the tested compounds (table 1)
Positive control Rosiglitazone 50 µM (as stimulator differentiation and adipogenesis) added at the same time as the tested compounds (table 1)
Vanadium reference compounds Vanadyl sulfate 50 µM (VOSO4) (as inorganic vanadium compound), Bis(maltolato)oxovanadium(IV) 50 µM (BMOV) (as complex vanadium compound)
Table 1. 3T3-L1 preadipocytes differentiation method and experiments scheme
Table 2. The controls used in experiments
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calculated as differences between incubation medium without 
cells and medium with cells after incubation with tested com-
pound. 
Cell number
The estimation of the cell number was performed on the basis 
cell reaction with PrestoBlue Cell Viability Reagent (Thermo 
Fisher Scientific), a cell-permeable resazurin-based reagent 
that functions as a cell viability indicator by using the reducing 
power of living cells (mitochondrial enzyme activity) to quanti-
tatively measure the proliferation of cells (cell numbers). After 
incubation of the cells with test compounds, 10 μl of PrestoBlue 
reagent was added to each microplate well, and the microplate 
was placed on an orbital shaker for content mixing. Plates were 
incubated for 20 minutes, and the fluorescence intensity at 560 
nm excitation and 590 nm emission was determined using a mul-
ti-mode microplate reader POLARstar Omega (BMG Labtech, 
Germany). The results were normalized to the untreated control 
(cells with solvent only), wherein the intensity of fluorescence 
was taken as 100%.
Statistical methods
For all results statistical analysis was performed by analysis of 
variance followed by the Tukey test for post hoc comparisons 
with p<0.05. All tests were performed using GraphPad Prism 
version 6.0 for Windows, GraphPad Software, San Diego, Cal-
ifornia USA.
Results and Discussion
Vanadium complex (1) exerted potent inhibition of all tested 
tyrosine phosphatases, namely PTP1B, LAR, SHP1, and SHP2 
(Table 3). Importantly, the percentage of inhibition of activity 
of these enzymes by compound (1) at a concentration of 10 μM 
was similar to that by inorganic vanadium compound VOSO4 
and BMOV. This methyl analog of ethyl maltolate (BEOV) has 
been tested as an antidiabetic agent in phase II clinical trial and 
was used as a comparator of the activity for our new complex (1) 
[27]. Incubation of phosphatases with complex (1) at the concen-
tration of 10 μM led to the almost total inhibition of the activity 
of the investigated enzymes; therefore, there are limited meth-
ods to distinguish the inhibitory action of the tested compounds. 
Control compounds VOSO4 and BMOV at a concentration of 
1 μM showed similar inhibitory activity for all tested phos-
phatases, and only LAR phosphatase activity was more strongly 
inhibited by both control vanadium compounds (Table 3). 
With regard to the results obtained for the comparative com-
pounds, the results for complex (1) showed significant differenc-
es in the inhibition of particular phosphatases. The degree of 
inhibition of SHP1 and SHP2 phosphatases (61% and 66%, re-
spectively) was approximately two-fold higher than that of PT-
P1B and LAR (36% and 31%, respectively). While the inhibition 
of SHP1 and SHP2 phosphatases by complex (1) was slightly 
less than that caused by BMOV, the differences between the two 
compounds were distinctly greater for inhibition of PTP1B and 
LAR phosphatases (Table 3). 
The observed differences in the degree of inhibition of ty-
rosine phosphatases (SHP1 and SHP2 vs. PTP1B and LAR) ob-
tained in the screening tests seemed to be too small to indicate 
the selectivity of this complex. However, this does not indicate 
biological activity on 3T3-L1 cells (results given below), and 
further studies of the relationship between the adipogenesis pro-
cess and the differences in the degree of inhibition of tyrosine 
phosphatases by various vanadium complexes seem to be rea-
sonable and needed.
To assess the influence of tested complex (1) on the adipogen-
esis process, 3T3-L1 preadipocytes were used. Incubation of the 
cells was carried out in two stages of differentiation of preadipo-
cytes to adipocytes (adipogenesis). After short-term exposure of 
the cells to inducers of adipogenesis for 24 hours (IBMX, dex-
amethasone, and insulin as described in Materials and Methods 
section), the inducers were withdrawn from the medium and re-
placed with tested or reference compounds at the concentration 
of 50 µM. After a further 24 hours of incubation, intracellular 
lipid content in 3T3-L1 cells was determined as a marker of ad-
ipogenesis (Figure 1). The lipid content in cells incubated with 
complex (1) (493% ± 22%) was significantly higher than that in 
the control cells subjected to differentiation (328% ± 23%) and 
Phosphatase (% of inhibition±SD)
PTP1B LAR SHP2 SHP1 PTP1B LAR SHP2 SHP1
Compound 10 µM 1 µM
VOSO4 79±1 92±1 95±3 92±1 62±3 44±3 77±1 70±2
BMOV 90±2 96±2 95±1 91±2 77±2 58±2 82±2 76±1
Complex (1) 72±1 96±1 91±1 85±1 36±3 31±3 66±3 61±2
Table 3. The results an in vitro human phosphatases (PTP) inhibition activity assay 
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over two times higher than that in cells incubated with rosiglita-
zone and BMOV (200% ± 21% and 219 ± 21%, respectively). All 
comparisons in the presented results were expressed in relation 
to untreated control without any differentiation inducers, and 
statistical differences between the results mentioned above are 
considered at p<0.001. 
A well-studied and described effect of adipogenic compounds 
is the stimulation of proliferation of preadipocytes, and this 
effect was demonstrated in this experiment for rosiglitazone 
(249% ± 13%) (Figure 2). The same effect was also observed 
for BMOV and complex (1) (283% ± 15% and 200% ± 17% of 
untreated control, respectively, p <0.001). 
Figure 1. Intracellular lipid content in 3T3-L1 cells subjected to differentiation to adipocytes after incubation 
with control compounds (isoproterenol, rosiglitazone and BMOV) and vanadium complex (1). The selected 
statistical significance is marked on the figure for day 3. Tukey’s post-hoc test was used. ***p<0.001 vs BMOV, 
rosiglitazone and undifferentiated control
Figure 2. Number of 3T3-L1 cells subjected to differentiation after incubation with control compounds 
(isoproterenol, rosiglitazone and BMOV) and vanadium complex (1). The selected statistical significance is 
marked on the figure. Tukey’s post-hoc test was used. ***p<0.001 vs undifferentiated control and BMOV (day 3), 
***p<0.001 vs undifferentiated control and rosiglitazone (for day 8)
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This proliferative effect together with the increase in intracel-
lular lipid accumulation confirms the effect of complex (1) on 
the intensification of adipogenesis.
Further incubation of complex (1) and comparative com-
pounds was performed at a later stage of the differentiation pro-
cess of preadipocytes to adipocytes. After approximately 7–10 
days of 3T3-L1 preadipocyte differentiation, this process was 
completed, and most cells exhibited mature adipocyte pheno-
type with numerous intracellular lipid droplets. A 24-hour incu-
bation with the examined compounds on day 7 after the initia-
tion of the differentiation process showed that the intracellular 
lipid content influenced by rosiglitazone, BMOV, and complex 
(1) was approximately two-fold higher than that in 3T3-L1 cells 
not treated with any adipogenesis inducers (untreated control). 
For isoproterenol used as a negative control (lipolytic activity), 
the intracellular lipid content was approximately half of that in 
differentiated control cells. Differences in the effect on lipid ac-
cumulation between rosiglitazone, BMOV, differentiated con-
trol, and complex (1) on day 8 of the experiment were aligned, 
which indicate that the adipogenesis process was completed at 
this stage, and these compounds did not cause further increase 
in lipid accumulation. Further, the lack of significant differences 
in the cell number on days 3 and 8 of differentiation confirmed 
this conclusion.
Glucose utilization in 3T3-L1 preadipocytes under the influ-
ence of complex (1) on day 3 of differentiation was significantly 
higher than that in differentiated control as well as untreated 
control (p<0.001) (Figure 3). The same differences were also 
seen on day 8 of the experiment. This indicates that complex 
(1) exerts effect on both preadipocytes and differentiated adi-
pocytes, showing both pro-adipogenic and insulinomimetic ef-
fects. Rosiglitazone and BMOV also showed similar differenc-
es, with the effect of BMOV on glucose utilization significantly 
higher than that for complex (1).
The obtained results indicate that complex (1) is an effective 
factor strengthening the previously initiated process of differen-
tiation of preadipocytes into adipocytes, which is accompanied 
by an increase in cell proliferation and intracellular lipid accumu-
lation. These results are consistent with those of other studies in 
which vanadium compounds showed similar properties [19, 21].
With regard to the published results [29], our study is the first 
with the 3T3-L1 cell model in which vanadium complex was 
used not as a stand-alone adipogenic agent, but was used after 
a short period of induction by “classical” agents initiating the 
differentiation of preadipocytes. This approach seems to be im-
portant because of the fact that pharmacological interventions in 
metabolic disorders usually occur when the process of differen-
tiation has already been initiated or progressed.
Conclusion
The present preliminary results support the hypothesis that va-
nadium complexes offer new opportunities for the development 
of therapeutic strategies for the treatment of type 2 diabetes 
Figure 3. Glucose utilisation in 3T3-L1 cells subjected to differentiation to adipocytes after incubation with 
control compounds (isoproterenol, rosiglitazone and BMOV) and vanadium complex (1). The selected statistical 
significance is marked on the figure. Tukey’s post-hoc test was used. ***p<0.001 vs undifferentiated control and 
rosiglitazone (day 3) and *p<0.05 vs BMOV (day 3), ***p<0.001 vs undifferentiated control and BMOV (day 8)
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and other metabolic diseases that involve adipocytes in patho-
physiological mechanisms. Because there are a limited number 
of studies on the influence of vanadium complexes on adipose 
physiology, more extensive and comprehensive studies are re-
quired. 
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